These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 35840049)

  • 21. The efficacy and safety of neoadjuvant immunochemotherapy in resectable stage I-III non-small cell lung cancer: a systematic review and network meta-analysis.
    Li B; Gu Y; Zhao W; Li Z; Guo W; Lu X; Jiang J
    Clin Transl Oncol; 2024 Sep; ():. PubMed ID: 39251495
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety and short-term outcomes of esophagectomy after neoadjuvant immunotherapy combined with chemotherapy or chemoradiotherapy for locally advanced esophageal squamous cell cancer: analysis of two phase-II clinical trials.
    Shen D; Chen R; Wu Q; Ji Y; van der Wilk BJ; Chen EY; Chen Q; Chen M
    J Gastrointest Oncol; 2024 Jun; 15(3):841-850. PubMed ID: 38989436
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of neoadjuvant immunotherapy in resectable gastric/gastroesophageal junction tumors: a meta-analysis and systematic review.
    Wang J; Tong T; Zhang G; Jin C; Guo H; Liu X; Zhang Z; Li J; Zhao Y
    Front Immunol; 2024; 15():1339757. PubMed ID: 38352873
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Neoadjuvant chemoradiotherapy combined with operation vs. operation alone for resectable esophageal cancer: Meta-analysis on randomized controlled trials].
    Duan X; Yu Z
    Zhonghua Wei Chang Wai Ke Za Zhi; 2017 Jul; 20(7):809-815. PubMed ID: 28722096
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and safety of neoadjuvant immunotherapy in resectable esophageal or gastroesophageal junction carcinoma: A pooled analysis of prospective clinical trials.
    Zhu J; Leng X; Gao B; Wang B; Zhang H; Wu L; Ma J; Tan Y; Peng L; Han Y; Wang Q
    Front Immunol; 2022; 13():1041233. PubMed ID: 36591306
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and Safety of Neoadjuvant Chemoimmunotherapy in Resectable Esophageal Squamous Cell Carcinoma: A Meta-analysis.
    Xu J; Yan C; Li Z; Cao Y; Duan H; Ke S
    Ann Surg Oncol; 2023 Mar; 30(3):1597-1613. PubMed ID: 36380254
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Morbidity and Mortality of Patients Who Underwent Minimally Invasive Esophagectomy After Neoadjuvant Chemoradiotherapy vs Neoadjuvant Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma: A Randomized Clinical Trial.
    Wang H; Tang H; Fang Y; Tan L; Yin J; Shen Y; Zeng Z; Zhu J; Hou Y; Du M; Jiao J; Jiang H; Gong L; Li Z; Liu J; Xie D; Li W; Lian C; Zhao Q; Chen C; Zheng B; Liao Y; Li K; Li H; Wu H; Dai L; Chen KN
    JAMA Surg; 2021 May; 156(5):444-451. PubMed ID: 33729467
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety and feasibility of esophagectomy following combined neoadjuvant immunotherapy and chemotherapy for locally advanced esophageal cancer: a propensity score matching.
    Hong ZN; Zhang Z; Chen Z; Weng K; Peng K; Lin J; Kang M
    Esophagus; 2022 Apr; 19(2):224-232. PubMed ID: 34988773
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of neoadjuvant immunotherapy plus chemotherapy versus chemotherapy alone for patients with locally advanced esophageal squamous cell carcinoma: A propensity score matching.
    Jing SW; Zhai C; Zhang W; He M; Liu QY; Yao JF; Wang R; Tian ZQ; Wang J; Liu JF
    Front Immunol; 2022; 13():970534. PubMed ID: 36275724
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Efficacy and safety of total neoadjuvant therapy versus neoadjuvant chemoradiotherapy in the treatment of locally advanced rectal cancer: a meta-analysis].
    Zhang YQ; Sun KG; Lu JY; Ma J; Yao N; Qin ZH; Yao YH
    Zhonghua Wei Chang Wai Ke Za Zhi; 2022 Jun; 25(6):531-538. PubMed ID: 35754218
    [No Abstract]   [Full Text] [Related]  

  • 31. Neoadjuvant immunotherapy for resectable esophageal cancer: A review.
    Li Q; Liu T; Ding Z
    Front Immunol; 2022; 13():1051841. PubMed ID: 36569908
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Does neoadjuvant therapy contribute to increased risk in anastomotic leakage of esophageal cancer? A network meta-analysis.
    Zhou D; Chen D; Song P; Hu Z; Xu S; Zhu R; Chen Y
    J Evid Based Med; 2024 Sep; 17(3):559-574. PubMed ID: 39161209
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Recent Progress in the Neoadjuvant Treatment Strategy for Locally Advanced Esophageal Cancer.
    Hou S; Pan Z; Hao X; Hang Q; Ding Y
    Cancers (Basel); 2021 Oct; 13(20):. PubMed ID: 34680311
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of outcomes between neoadjuvant chemoradiotherapy and neoadjuvant chemotherapy in patients with locally advanced esophageal cancer: A network meta-analysis.
    Fan N; Wang Z; Zhou C; Bludau M; Contino G; Zhao Y; Bruns C
    EClinicalMedicine; 2021 Dec; 42():101183. PubMed ID: 34805809
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Diffusion-weighted MRI and
    Xu X; Sun ZY; Wu HW; Zhang CP; Hu B; Rong L; Chen HY; Xie HY; Wang YM; Lin HP; Bai YR; Ye Q; Ma XM
    Radiat Oncol; 2021 Jul; 16(1):132. PubMed ID: 34281566
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neoadjuvant immunotherapy for resectable esophageal cancer: A protocol of meta-analysis.
    Yu G; Yu W; Xu X; Ye B; Yao L
    PLoS One; 2021; 16(6):e0252829. PubMed ID: 34086821
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical evidence for association of neoadjuvant chemotherapy or chemoradiotherapy with efficacy and safety in patients with resectable esophageal carcinoma (NewEC study).
    Zhou HY; Zheng SP; Li AL; Gao QL; Ou QY; Chen YJ; Wu ST; Lin DG; Liu SB; Huang LY; Li FS; Zhu HY; Qiao GB; Lanuti M; Yao HR; Yu YF
    EClinicalMedicine; 2020 Jul; 24():100422. PubMed ID: 32637899
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of esophageal cancer survival after neoadjuvant chemoradiotherapy plus surgery versus definitive chemoradiotherapy: A systematic review and meta-analysis.
    Ke J; Xie Y; Huang S; Wang W; Zhao Z; Lin W
    Asian J Surg; 2024 Sep; 47(9):3827-3840. PubMed ID: 38448293
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Application of neoadjuvant chemoradiotherapy and neoadjuvant chemotherapy in curative surgery for esophageal cancer: A meta-analysis.
    Yuan MX; Cai QG; Zhang ZY; Zhou JZ; Lan CY; Lin JB
    World J Gastrointest Oncol; 2024 Jan; 16(1):214-233. PubMed ID: 38292844
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Alleviation of neoadjuvant immunochemotherapy for esophageal squamous cell carcinoma and its relationship with expression and changes of PD-L1.
    Zhou YH; Li JY; Yan JX; Guo P; He WW; Liu Y
    Neoplasma; 2022 Jul; 69(4):785-793. PubMed ID: 35400168
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.